In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus  by Li, Hui et al.
Journal of Microbiology, Immunology and Infection (2015) 48, 655e661Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEIn vitro interactions between fluconazole
and minocycline against mixed cultures of
Candida albicans and Staphylococcus
aureus
Hui Li a, Caiqing Zhang b, Ping Liu a, Weiguo Liu c, Yuan Gao a,
Shujuan Sun c,*a School of Pharmaceutical Sciences, Shandong University, Jinan 250012, Shandong Province,
China
b Department of Respiratory Medicine, Qianfoshan Hospital Affiliated to Shandong University,
Jinan 250014, Shandong Province, China
c Department of Pharmacy, Qianfoshan Hospital Affiliated to Shandong University,
Jinan 250014, Shandong Province, ChinaReceived 29 August 2013; received in revised form 9 October 2013; accepted 26 March 2014
Available online 22 May 2014KEYWORDS
Antimicrobial
resistance;
Calcium regulation;
Candida albicans;
Drug combination;
Polymicrobial biofilms* Corresponding author. Department
250014, Shandong Province, China.
E-mail address: sunshujuan888@16
http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground/purpose: It is difficult to manage coinfections in critically ill patients, especially
in the presence of mixed-species biofilms. The aim of this study was to seek an effective drug
combination for managing the dual-species biofilm of Candida albicans and Staphylococcus
aureus.
Methods: The interaction between fluconazole and minocycline against polymicrobial plank-
tonic cells and polymicrobial biofilms formed over four different time intervals (4 hours,
8 hours, 12 hours, and 24 hours) was investigated using a microdilution checkerboard method.
To explore whether the combined effects against the polymicrobial cultures involved calcium
regulation, the effects of benidipine and ethylene glycol tetraacetic acid were characterized
using a plate streaking method and a liquid-based quantitative method.
Results: Fluconazole combined with minocycline exerted strong effects against polymicrobial
planktonic cells and polymicrobial biofilms formed over 4 hours, 8 hours, and 12 hours. The
addition of benidipine and ethylene glycol tetraacetic acid enhanced the activity of the drug
combination, suggesting that the combined effects may involve the perturbation of calcium
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Candida albicans is the fourth most common cause of
bloodstream infections and is associated with the highest
mortality.1,2 It has been reported that 27% of nosocomial C.
albicans bloodstream infections are polymicrobial, with
Staphylococcus aureus being the third most common
microorganism isolated with C. albicans.3 Not only are C.
albicans and S. aureus independently responsible for a
myriad of monomicrobial infections, but there is also
increasing evidence in the literature to suggest that they
are commonly associated with polymicrobial infections.4
The extensive use of indwelling medical devices offers
favorable conditions for biofilm formation, and it has been
estimated that biofilms account for> 80% of all infections in
thehumanbody.5C.albicanshasapowerful ability todevelop
biofilmsonbiomaterials, and S. aureuspreferentially adheres
to C. albicans hyphae, which can result in the formation of C.
albicanseS. aureus polymicrobial biofilms.6 Biofilm-
embedded microorganisms possess notorious resistance to
many antimicrobial agents and the ability to resist the im-
mune response in the body. Furthermore, the organisms
within polymicrobial biofilms exhibit uniquely altered gene
expression, amplified pathogenic phenotypes, and altered
antibiotic susceptibility during multispecies interactions.7e9
For example, C. albicans in combination with S. aureus pro-
duces synergism and increased morbidity and mortality in
mice.10,11 Antimicrobial selection for infections caused by
polymicrobial biofilms presents a challenge to clinical man-
agement because polymicrobial biofilms are more compli-
cated and difficult to eradicate thanmonomicrobial biofilms.
Therefore, there is an urgent need to explore management
options for polymicrobial biofilms. Considerable effort has
been made to counteract biofilms, and drug combination
therapy is one effective approach.12,13 The aim of this study
was to seek an effective drug combination for the manage-
ment of C. albicanseS. aureus polymicrobial biofilms.
Fluconazole is the most common first-line drug for the
treatment and prevention of C. albicans infections. Howev-
er, due to itswidespreaduse in clinical settings, an increasing
number of fluconazole-resistant strains are being isolated.
Similarly, an increasing prevalence ofmethicillin-resistant S.
aureus (MRSA) has been observed over recent years, and
MRSA can result in serious healthcare-associated in-
fections.14,15 Our previous research has demonstrated that
fluconazole can work synergistically with minocycline
against fluconazole-resistant C. albicans, and minocycline
enhances the amount of fluconazole that penetrates C.
albicans biofilms.16 This observation has prompted us to
consider whether the combination of fluconazole and mino-
cycline could have a strong effect on C. albicanseS. aureus
polymicrobial biofilms. In the present study, the effects of
fluconazole in combination with minocycline were investi-
gated when used against dual-species planktonic and biofilmcultures in addition to single-species cultures. Additionally,
the impact of calcium regulation on the drug combination
against dual-species cultures was investigated to provide
data for future research into its mechanism of action.
Methods
Fungal and bacterial isolates and suspension
preparation
Four C. albicans clinical isolates (2 azole-susceptible
strains, CA8/CA14, plus 2 azole-resistant strains, CA10/
CA137) and four S. aureus isolates (2 oxacillin-susceptible
strains, SA4/SA5, plus 2 oxacillin-resistant strains, SA6/
SA10) were used. The susceptibility of these strains was
determined according to the Clinical and Laboratory Stan-
dards Institute (CLSI) M27-A3 and M100-S19 guidelines with
C. albicans ATCC 10231 and S. aureus ATCC 25923 as
reference strains.17,18 All eight strains were tested in this
study, and they were identified and then confirmed. Frozen
stocks of the isolates were maintained at 70C.
Prior to each experiment, all Candida and Staphylo-
coccus strains were subcultured at least twice at 35C on
their respective culture media, with fungi on
yeastepeptoneedextrose (YPD) agar medium containing 1%
(w/v) yeast extract, 2% peptone, 2% dextrose, and 2% agar
and bacteria on nutrient agar medium containing 1%
peptone, 0.3% beef extract, 0.5% NaCl, and 1.5% agar. After
w18 hours, the fungal and bacteria cells were harvested
and suspended in sterile phosphate-buffered saline (pH
7.2). The concentration of the Candida suspension was
measured using a hemocytometer, and Staphylococcus cells
were counted using the live/dead Baclight staining method.
Preparation of drug stock solutions
Fluconazole was kindly provided by Cheng Chuang Phar-
maceutical Co. Ltd., Jinan, China, and minocycline and
benidipine were kindly provided by An Bei Ka Pharmaceu-
tical Co. Ltd., Jinan, China. Stock solutions of fluconazole
and benidipine were prepared in sterile distilled water and
dimethyl sulfoxide, respectively, at a concentration of
2560 mg/mL, and minocycline was prepared in dimethyl
sulfoxide at a concentration of 6400 mg/mL. All stock so-
lutions were stored at 70C until use.
Determination of minimal inhibitory
concentrations against dual-species planktonic
cultures of C. albicans and S. aureus
As a result of preliminary experiments with a range of
media, RPMI 1640 medium (GIBCO, Life Technologies, The
Table 1 Combined drug effects against polymicrobial
planktonic cells
Polymicrobial
PCa
MICb (mg/mL)
Alone In combination
FLC MINO FLC MINO
RCA137-RSA10 >256 >64 2 4
RCA137-SSA4 >256 >64 1 4
SCA8-RSA10 >256 >64 0.5 2
SCA8-SSA4 >256 >64 0.5 1
RCA10-RSA12 >256 >64 4 4
RCA10-SSA5 >256 >64 2 1
SCA14-RSA12 >256 >64 4 4
SCA14-SSA5 >256 >64 0.5 1
a Polymicrobial planktonic Candida albicans and Staphylo-
coccus aureus cells.
b MIC80% of each drug alone or in combination against poly-
microbial planktonic C. albicans and S. aureus cells shown as
the median of three independent experiments.
CA Z C. albicans; FLC Z fluconazole; MIC Z minimum inhibi-
tory concentration; MINO Z minocycline; R Z resistant strain;
RCA-RSA Z polymicrobial cultures of FLC-resistant C. albicans
and oxacillin-resistant S. aureus; S Z susceptible strain;
SA Z S. aureus.
Resistance reversal by drug combination 657Netherlands) buffered with 0.165 M morpholinepropane-
sulfonic acid (Ding Guo Biological Co. Ltd., Beijing, China)
was selected as the liquid medium that was best able to
support the growth of both species. One of the four
C. albicans isolates was combined with one of the four
S. aureus isolates to create eight groups of dual-species
cultures as described in Table 1. The mixed-species cells
were regarded as an integrality, and a checkerboard broth
microdilution assay was used to determine the minimum
inhibitory concentrations (MICs) of fluconazole and
minocycline alone and in combination against planktonic
cells. In accordance with CLSI M27-A3, serial twofold
dilutions were performed for each drug, and 50 mL of each
drug dilution was added.17 The final concentration
of fluconazole ranged from 0.25 mg/mL to 256 mg/mL, and
minocycline ranged from 1 mg/mL to 64 mg/mL in the plate.
The C. albicans and S. aureus suspensions were diluted and
mixed to obtain twice the final inoculum of 1  103 colony-
forming units (CFU)/mL for C. albicans and 1  105 CFU/mL
for S. aureus, and 100 mL of the mixed-species inoculum
was added to 96-well plates. The plates were incubated at
35C for 48 hours. After 48 hours, a reagent containing 12.5
parts XTT (2,3- bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) to one
part menadione was added to each well followed by incu-
bation for 2 hours in the dark. Colorimetric changes were
measured at 492 nm with a microtiter plate reader (Mul-
tiskan MK3; Thermo Labsystems). The MIC was defined as
the lowest drug concentration that produced an 80%
reduction in absorption compared with that of the drug-
free control well. The experiments were performed in
triplicate on different days.
Determination of sessile MICs against dual-species
biofilms of C. albicans and S. aureus
The checkerboard microdilution assay was also used to
determine the sessile MICs (SMICs) of fluconazole and
minocycline alone and in combination against polymicrobial
biofilms. The same eight polymicrobial culture models
above were used to form 4-hour, 8-hour, 12-hour, and 24-
hour polymicrobial biofilms on 96-well flat-bottomed plates
at 35C. The biofilm-forming concentration was
1  103 CFU/mL for C. albicans and 1  105 CFU/mL for S.
aureus. After the formation of biofilms, the medium was
aspirated, and each well was washed three times with
sterile phosphate-buffered saline to remove loosely
adhered cells, followed by the addition of 100 mL fresh
medium. Subsequently, each serially diluted drug was
added, bringing the final concentration of fluconazole in
the wells to a range of 0.5e512 mg/mL and that of mino-
cycline to a range of 2e128 mg/mL. The whole system was
incubated for 48 hours at 35C. After 48 hours, the biofilms
were quantified using the XTT reduction assay.19 The defi-
nition of SMIC was the same as that of MIC. Each experiment
was performed in triplicate on different days.
Effects of calcium regulation on drug interactions
The effects of benidipine and ethylene glycol tetraacetic
acid (EGTA) on the drug combination against the dual-species cultures were preliminarily investigated using the
plate streaking method. A culture medium composed of
0.25% (w/v) yeast extract, 1.25% peptone, 0.5% dextrose,
0.375% NaCl, 0.25% beef, and 1.625% agar was selected as
the solid medium best able to support the growth of both
species as shown in Fig. 1. The final concentrations were
2 mg/mL fluconazole, 8 mg/mL minocycline, 8 mg/mL beni-
dipine, and 0.5 mM for EGTA. For qualitative evaluation,
four Candida strains with different susceptibilities were
combined with one Staphylococcus strain to create four
polymicrobial culture groups. The polymicrobial suspension
(1.5  106 CFU/mL yeast and 1.5  108 CFU/mL Staphylo-
coccus) was coated onto the delimited area of the plate.
The plates were incubated at a constant temperature of
35C for 48 hours, after which the growth of the mixed
cultures was observed visually.
To quantify the effects of benidipine and EGTA on the
drug combination, the microdilution assay in 96-well plates
was performed. The effects of benidipine (0 mg/mL, 4 mg/
mL, and 8 mg/mL) and EGTA (0 mM, 0.25 mM, and 0.5 mM)
on the two groups of drug combinations composed of
different concentrations of fluconazole and minocycline
were evaluated against dual-species planktonic and biofilm
cultures of CA10 and SA12. Benidipine/EGTA alone and
fluconazole in combination with minocycline were used as a
control. The concentrations of fluconazole and minocycline
in the two groups ranged from low to high. The planktonic
and biofilm dual-species cells were prepared as described
above. The 96-well plates were incubated for 48 hours at
35C. The viability of the mixed-species cells was deter-
mined using the XTT reduction assay as described above.
For the three independent experiments, one-way analysis
of variance followed by the NewmaneKeuls multiple com-
parison test were used to determine the differences be-
tween different treatment groups at the chosen
significance level (p < 0.05).
Figure 1. Propagation conditions for Staphylococcus aureus (left) and Candida albicans (right) on different culture media. By
comprehensively comparing strain growth after incubation for 24 hours and 48 hours at 35C, the most vigorous propagation
occurred in Group D. AeE: different nutritional ingredient groups. Group A: 1% yeast extract, 2% peptone, 2% dextrose, and 2% agar.
Group B: 0.75% yeast extract, 1.75% peptone, 1.5% dextrose, 0.125% NaCl, 0.075% beef, and 1.875% agar. Group C: 0.5% yeast
extract, 1.5% peptone, 1% dextrose, 0.25% NaCl, 0.15% beef, and 1.75% agar. Group D: 0.25% yeast extract, 1.25% peptone, 0.5%
dextrose, 0.375% NaCl, 0.25% beef, and 1.625% agar. Group E: 1% peptone, 0.5% NaCl, 0.3% beef, and 1.5% agar.
Table 2 Combined drug effects against the polymicrobial
biofilms
Polymicrobial
BFa
SMICb (mg/mL)
Alone In combination
FLC MINO FLC MINO
RCA137-RSA10 >512 >128 4 8
RCA137-SSA4 >512 >128 2 8
SCA8-RSA10 >512 >128 1 8
SCA8-SSA4 >512 >128 1 2
RCA10-RSA12 >512 >128 8 8
RCA10-SSA5 >512 >128 4 4
SCA14-RSA12 >512 >128 8 8
SCA14-SSA5 >512 >128 1 2
a Polymicrobial biofilms formed for 12 hours.
b SMIC80% of each drug alone or in combination against 12-hour
polymicrobial C. albicanseS. aureus biofilms shown as the me-
dian of three independent experiments.
CA Z C. albicans; MINO Z minocycline; R Z resistant strain;
RCA-RSA Z polymicrobial cultures of FLC-resistant C. albicans
and oxacillin-resistant S. aureus; S Z susceptible strain; SA Z
S. aureus; SMIC Z sessile minimum inhibitory concentration.
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In vitro combined effects of fluconazole and
minocycline against dual-species planktonic
cultures
The MIC80%s of fluconazole against C. albicans CA8, CA10,
CA14, and CA137 were 0.25 mg/mL, 512 mg/mL, 0.5 mg/mL,
and 64 mg/mL, respectively, and 0.5 mg/mL, 0.5 mg/mL,
4 mg/mL, and 4 mg/mL, for minocycline against S. aureus
SA4, SA5, SA10, and SA12, respectively. The MICs of the two
quality control strains fell within the normal range. The
combination of fluconazole and minocycline produced
synergistic effects against fluconazole-resistant C. albi-
cans, whereas fluconazole did not potentiate the effect of
minocycline against S. aureus. Each drug alone did not
produce obvious effects against the dual-species planktonic
cultures, whereas the combination of both produced strong
effects. The results are summarized in Table 1. As shown in
Table 1, the addition of minocycline resulted in a decrease
in the MIC of fluconazole from 512 mg/mL to 2e4 mg/mL
against the mixed fungal-bacterial culture containing C.
albicans CA10.
In vitro combined effects of fluconazole and
minocycline against dual-species biofilms
Minocycline potentiated the effect of fluconazole against
C. albicans biofilms, whereas fluconazole did not enhance
the effect of minocycline against S. aureus biofilms. Flu-
conazole and minocycline alone had little effect on the
dual-species biofilms, whereas fluconazole in combination
with minocycline had a potent effect on all of the poly-
microbial biofilms formed for 4 hours, 8 hours, and
12 hours. The combined effects against the 4-hour and 8-
hour biofilms were similar to those against planktonic
cells (data not shown). The results of the experimentsinvolving the 12-hour biofilms are summarized in Table 2.
The combination of 8 mg/mL fluconazole and 8 mg/mL
minocycline produced approximately 80% inhibition of the
growth of biofilms formed by fluconazole-resistant C. albi-
cans CA10 and oxacillin-resistant S. aureus SA12 compared
with the control well. However, no obvious effect was
observed against the 24-hour biofilms.
Impact of calcium regulation on drug interactions
The results of a preliminary investigation are shown in
Fig. 2. Compared with the growth control group, cotreat-
ment with fluconazole and minocycline inhibited the
Figure 2. Effects of BEN/EGTA on the combination of FLC and MINO against mixed cultures of Candida albicans CA10-SA4, CA137-
SA4, CA8-SA4, and CA14-SA4 after incubation for 48 hours. The framework on the left characterizes the arrangement of the mixed
species of C. albicans and Staphylococcus aureus in the culture dish. The concentrations of FLC, MINO, BEN, and EGTA in the plates
were 2 mg/mL, 8 mg/mL, 8 mg/mL, and 0.5 mM, respectively. BEN Z benidipine; EGTA Z ethylene glycol tetraacetic acid;
FLC Z fluconazole; MINO Z minocycline.
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benidipine or EGTA increased the effectiveness of the drug
combination. The potentiation caused by the addition of
EGTA appeared to be stronger than that caused by the
addition of benidipine, with the combination of flucona-
zole, minocycline, and EGTA almost completely inhibiting
growth.
The results of the quantitative liquid assays indicated
that the addition of benidipine/EGTA produced large in-
creases in percent growth inhibition compared with the
control groups (Fig. 3), and the higher the concentration of
the added benidipine/EGTA, the greater the effect against
planktonic cells. The addition of 0.25/0.5 mM EGTA to the
combination of fluconazole and minocycline produced a
statistically significant difference, whereas the addition of
4/8 mg/mL benidipine did not. The same phenomenon was
observed for 8-hour and 12-hour dual-species biofilms, but
for 24-hour biofilms, adding benidipine and EGTA did not
reduce growth (data not shown).Discussion
Most previous research has focused on single-species bac-
terial or fungal biofilms, and little research has involvedmixed fungalebacterial biofilms. Furthermore, the current
research associated with polymicrobial biofilms is primarily
dedicated to determining how fungi and bacteria interact in
biofilms.20,21 Few studies have investigated drug interven-
tion against polymicrobial biofilms. The results of the pre-
sent study indicate that fluconazole in combination with
minocycline are highly effective against dual-species
planktonic and biofilm cultures of C. albicans and S.
aureus. Fluconazole in combination with minocycline pro-
duced a synergistic effect on resistant C. albicans plank-
tonic cells and their biofilms, whereas fluconazole did not
enhance the effect of minocycline against S. aureus cul-
tures. The potent efficacy of the drug combination against
the two species may be explained by the fact that mino-
cycline can potentiate the effect of fluconazole against C.
albicans and that minocycline itself can inhibit the growth
of S. aureus.
In this study, a new medium for culturing the mixed
species was explored, and the optimal components and
proportion of the nutritional ingredients may be useful to
researchers in this field. As for the dual-species biofilms
that formed for no more than 12 hours, the combined ef-
fect of fluconazole and minocycline was potent. However,
no obvious effect against the 24-hour biofilms was
observed. The anti-biofilm effects may be attributed to the
Figure 3. Effects of (A) BEN and (B) EGTA on the two drug
combination groups composed of different concentrations of
FLC and MINO against polymicrobial planktonic C. albicans
CA10 and SA12 cells. The bar chart denotes the percent growth
inhibition of different drug combinations against the mixed-
species cultures. In Group A, the concentration of both FLC
and MINO was 1 mg/mL. In Group B, the concentration of both
FLC and MINO was 2 mg/mL. In each sample containing FLC and
MINO and BEN or EGTA, the effect was significant (p < 0.01)
compared with the control samples (the first three columns).
Group B: Addition of 0.25/0.5 mM EGTA to the combination of
FLC and MINO produced a significant difference, with p < 0.01
in Group A and p < 0.05 in Group B. BEN Z benidipine;
EGTA Z ethylene glycol tetraacetic acid; FLC Z fluconazole;
MINO Z minocycline.
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inhibits the formation of polymicrobial biofilms. This drug
combination may serve as an effective approach against
polymicrobial biofilms, including those formed by resistant
strains.
Calcium homeostasis is crucial for the normal growth of
C. albicans.22 Our previous study demonstrated that one of
the predominant mechanisms by which minocycline po-
tentiates fluconazole against C. albicans involves inter-
rupting the cellular calcium balance.16 The results of this
work demonstrate that the addition of benidipine or EGTA
enhances the activity of the drug combination, and the
effect is stronger for EGTA than for benidipine. Moreover,
no obvious difference was observed in the quantitative
liquid assays, which may be attributed to the different
methods used and the different concentrations of the
mixed-species suspension. These results suggest that the
mechanism of action of the drug combination involves
calcium dysregulation.
In conclusion, the combination of fluconazole and min-
ocycline produced a strong effect against mixed planktonic
cultures and biofilms of C. albicans and S. aureus. The ac-
tivity of the drug combination was enhanced by benidipine
and EGTA, which may provide a basis for future mechanistic
studies involving Ca2þ.Conflicts of interest
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